Tower Research Capital (TRC)’s Fulgent Genetics FLGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.4K | Buy |
2,479
+1,099
| +80% | +$23.9K | ﹤0.01% | 2955 |
|
|
2025
Q4 | $36.3K | Buy |
1,380
+529
| +62% | +$13.7K | ﹤0.01% | 2667 |
|
|
2025
Q3 | $19.2K | Sell |
851
-1,272
| -60% | -$26.2K | ﹤0.01% | 3346 |
|
|
2025
Q2 | $42.2K | Sell |
2,123
-751
| -26% | -$14.6K | ﹤0.01% | 3112 |
|
|
2025
Q1 | $48.6K | Buy |
2,874
+2,428
| +544% | +$41.4K | ﹤0.01% | 2249 |
|
|
2024
Q4 | $8.24K | Sell |
446
-1,703
| -79% | -$33.2K | ﹤0.01% | 4007 |
|
|
2024
Q3 | $46.7K | Sell |
2,149
-1,126
| -34% | -$25.2K | ﹤0.01% | 2755 |
|
|
2024
Q2 | $64.3K | Buy |
3,275
+1,609
| +97% | +$33.6K | ﹤0.01% | 2904 |
|
|
2024
Q1 | $36.2K | Sell |
1,666
-7,749
| -82% | -$192K | ﹤0.01% | 2497 |
|
|
2023
Q4 | $272K | Buy |
9,415
+8,972
| +2,025% | +$240K | ﹤0.01% | 1851 |
|
|
2023
Q3 | $11.8K | Sell |
443
-202
| -31% | -$6.9K | ﹤0.01% | 3949 |
|
|
2023
Q2 | $23.9K | Buy |
645
+82
| +15% | +$2.86K | ﹤0.01% | 3225 |
|
|
2023
Q1 | $18K | Sell |
563
-1,038
| -65% | -$33.4K | ﹤0.01% | 3553 |
|
|
2022
Q4 | $47K | Sell |
1,601
-1,768
| -52% | -$63.3K | ﹤0.01% | 2394 |
|
|
2022
Q3 | $128K | Buy |
3,369
+1,765
| +110% | +$88.5K | ﹤0.01% | 2344 |
|
|
2022
Q2 | $87K | Buy |
1,604
+591
| +58% | +$32.5K | ﹤0.01% | 2399 |
|
|
2022
Q1 | $63K | Buy |
1,013
+432
| +74% | +$28.4K | ﹤0.01% | 2547 |
|
|
2021
Q4 | $58K | Sell |
581
-87
| -13% | -$7.65K | ﹤0.01% | 2645 |
|
|
2021
Q3 | $60K | Sell |
668
-129
| -16% | -$11.7K | ﹤0.01% | 2806 |
|
|
2021
Q2 | $73K | Sell |
797
-1,371
| -63% | -$109K | ﹤0.01% | 2688 |
|
|
2021
Q1 | $210K | Buy |
2,168
+1,550
| +251% | +$160K | ﹤0.01% | 1969 |
|
|
2020
Q4 | $33K | Sell |
618
-8,097
| -93% | -$338K | ﹤0.01% | 3489 |
|
|
2020
Q3 | $349K | Buy |
8,715
+8,243
| +1,746% | +$258K | ﹤0.01% | 2050 |
|
|
2020
Q2 | $8K | Sell |
472
-8,596
| -95% | -$132K | ﹤0.01% | 4102 |
|
|
2020
Q1 | $98K | Buy |
9,068
+7,766
| +596% | +$108K | 0.01% | 1000 |
|
|
2019
Q4 | $17K | Buy |
+1,302
| New | +$15.5K | ﹤0.01% | 2020 |
|
|
2019
Q2 | – | Sell |
-1,070
| Closed | -$6K | – | 3873 |
|
|
2019
Q1 | $6K | Buy |
1,070
+433
| +68% | +$1.99K | ﹤0.01% | 2942 |
|
|
2018
Q4 | $2K | Buy |
637
+437
| +219% | +$1.53K | ﹤0.01% | 3352 |
|
|
2018
Q3 | $1K | Buy |
+200
| New | +$856 | ﹤0.01% | 3583 |
|
|
2018
Q2 | – | Sell |
-1,522
| Closed | -$6K | – | 3775 |
|
|
2018
Q1 | $6K | Buy |
+1,522
| New | +$6.7K | ﹤0.01% | 2653 |
|
|
2017
Q4 | – | Sell |
-951
| Closed | -$5K | – | 3668 |
|
|
2017
Q3 | $5K | Sell |
951
-7,598
| -89% | -$43.7K | ﹤0.01% | 3299 |
|
|
2017
Q2 | $55K | Buy |
8,549
+7,666
| +868% | +$61.8K | 0.01% | 705 |
|
|
2017
Q1 | $10K | Buy |
883
+369
| +72% | +$4.36K | ﹤0.01% | 1764 |
|
|
2016
Q4 | $6K | Buy |
+514
| New | +$4.85K | ﹤0.01% | 2942 |
|
Other funds holding FLGT
RI
VCM
ICM
Tower Research Capital (TRC)'s FLGT Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Fulgent Genetics (FLGT) stake by 80% in Q1 2026, buying an estimated $23.9K and bringing the position to 2,479 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2955.
Tower Research Capital (TRC) first reported a position in FLGT in Q4 2016 and has held it in 34 quarters since. The position peaked at $349K in Q3 2020. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.
- Tower Research Capital (TRC) held 2,479 shares of Fulgent Genetics worth $39.4K as of Q1 2026.
- Tower Research Capital (TRC) bought 1,099 Fulgent Genetics shares in Q1 2026, an estimated $23.9K.
- Fulgent Genetics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2955 holding.
- Tower Research Capital (TRC) first reported a position in Fulgent Genetics in Q4 2016 and has held it in 34 quarters since.
- Tower Research Capital (TRC)'s Fulgent Genetics position peaked at $349K in Q3 2020.
- 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.